1. With K Ph2 being an open-label trial, does this mean we will see Cohort 1 results as soon as they are available? Figure 1 month for recruiting/screening, then 6 weeks for trial and follow up? So we could get some patient data from Cohort 1 in late May, correct?
2. Yes, you should see the new 10-Q this week.
2. If B and P both failed (not anticipating this), does CTIX have enough funding to finish out K Ph2 - basically enough money to get through 2017 while finishing P, B-OM, B-UP, K phase 2?
3. I don't disagree, but you'll hear someone saying "no partnership now means no partnership ever".
3. If all Phase 2's failed, I would still imagine they could partner B-ABSSSI for Phase 3. With it being a new class of antibiotics, I would think BP would be willing to fork over some cash for this. Does anyone disagree, and if so, why?